Yoshiyoshi Hirokawa
I’ve been watching Hims & Hers Health, Inc. (NYSE:HIMS) closely for a comeback, initiating it with a buy at $32 per share in late March. This morning we just received news that Hims has a
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Summary
- Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price.
- The deal is a game changer, enabling Hims to offer Wegovy at $599/month versus $1,999/month.
- I think this deal hints at potential to do the same with Ozempic further boosting the stock, which is already up +30% in pre-market trading.
- I hereon share my sentiment on HIMS stock and why I think this partnership is Hims' comeback we've all been waiting for.
I’m a retired Wall Street PM specializing in TMT; since kickstarting my career, I’ve spent over two decades in the market navigating the technology landscape, focusing on risk mitigation through the dot com bubble, credit default of ‘08, and, more recently, with the AI boom. In one word, what I’d like my service to revolve around is momentum.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.